Investors in Pennsylvania-based AmerisourceBergen Corp. have sued in Delaware for access to books and records of the pharmaceutical firm, stating that they are considering launching a civil lawsuit over a scheme by its subsidiaries to skim and repackage cancer drugs for sale across the country.

A Minnesota-based pension fund on Tuesday filed a complaint saying there was “more than a credible basis” to believe Amerisource’s leadership was aware of a longstanding practice at its two divisions in Alabama, which resulted in $885 million in criminal and civil fines, as well as “untold reputational harm.”